Lab Reference Library / VEGF (Vascular Endothelial Growth Factor)
Detox, Mold & CIRS
VEGF (Vascular Endothelial Growth Factor)
VEGF · VEGF-A · Vascular Endothelial Growth FactorReference range, optimal functional medicine levels, and why VEGF is characteristically low rather than elevated in CIRS, how capillary hypoperfusion from inadequate VEGF signaling produces air hunger and post-exertional malaise, and why VIP nasal spray at the final protocol stage is the primary intervention for VEGF restoration.
CIRS Vascular MarkerCapillary Perfusion
Low CIRSBelow 31 pg/mL
Normal31 to 86 pg/mL
Elevated ConcernAbove 200 pg/mL
Unitspg/mL
← Back to Lab Reference Library
Category: Detox, Mold & CIRS | Also known as: Vascular Endothelial Growth Factor, VEGF-A, Vasculotropin
1. What This Test Measures
VEGF (vascular endothelial growth factor, primarily VEGF-A) is a heparin-binding glycoprotein that is the master regulator of vasculogenesis (new blood vessel formation during development), angiogenesis (new vessel sprouting from existing vessels in adults), and vascular maintenance. VEGF is produced by many cell types including macrophages, mast cells, smooth muscle cells, platelets, keratinocytes, adipocytes, and tumor cells, and signals through VEGFR-1 and VEGFR-2 tyrosine kinase receptors on endothelial cells. VEGFR-2 is the primary signaling receptor, mediating the angiogenic, permeability-increasing, and endothelial survival effects of VEGF. VEGF production is regulated by hypoxia through the HIF-1 transcription factor: when oxygen tension falls, HIF-1 accumulates and drives VEGF gene expression to promote angiogenesis and restore oxygen delivery.
In the CIRS framework, VEGF behaves in a counterintuitive and diagnostically important way. Rather than being elevated (as would be expected if the tissue hypoxia driving CIRS symptoms were triggering a normal compensatory angiogenic response), VEGF is characteristically low in CIRS patients. The mechanism is not fully resolved but involves biotoxin-mediated disruption of the normal HIF-1 to VEGF compensatory pathway, leaving capillary density insufficient to support adequate tissue oxygen delivery. Patients with low VEGF in CIRS experience tissue hypoxia at the capillary level without the normal angiogenic correction, explaining the air hunger, exercise intolerance, and post-exertional malaise that characterize the pulmonary and vascular component of biotoxin illness.
In non-CIRS contexts, elevated VEGF is the clinically significant finding: tumors produce VEGF to support angiogenesis for their oxygen and nutrient supply, making elevated VEGF a tumor angiogenesis marker; diabetic retinopathy is driven by retinal ischemia-induced VEGF overproduction; and wound healing produces a transient VEGF elevation to support tissue repair angiogenesis. The dual-context interpretation of VEGF (low in CIRS, elevated in cancer and wound healing) makes clinical context essential for accurate interpretation of any VEGF result.
2. Reference Range and CIRS Interpretation
| VEGF Level | Context | Interpretation |
|---|---|---|
| Below 31 pg/mL | CIRS evaluation | Low: capillary hypoperfusion pattern; tissue oxygen delivery impaired; CIRS-consistent when other markers abnormal |
| 31 to 86 pg/mL | General | Normal: adequate angiogenic signaling for vascular maintenance |
| 86 to 200 pg/mL | General | Mildly elevated: physiological (wound healing, intense exercise training) or early pathological; evaluate clinical context |
| 200 to 500 pg/mL | Clinical concern | Elevated: evaluate for tumor angiogenesis, diabetic microvascular disease, inflammatory conditions; clinical investigation required |
| Above 500 pg/mL | High concern | Markedly elevated: strongly evaluate for malignancy, particularly solid tumors with active angiogenesis |
VEGF levels vary significantly by specimen type (serum vs plasma) and by platelet count (platelets store significant VEGF; thrombocytosis produces falsely elevated serum VEGF). Serum VEGF is higher than plasma VEGF because platelet VEGF is released during clotting. The CIRS reference range of 31 to 86 pg/mL is for serum; confirm specimen type with ordering laboratory. VEGF also rises transiently after vigorous exercise and may be mildly elevated for 24 to 48 hours after intense physical activity.
3. Why VEGF Is Low in CIRS: The Capillary Hypoperfusion Mechanism
The paradox of low VEGF in CIRS is that patients are experiencing tissue hypoxia (driving the air hunger and exercise intolerance that are hallmark symptoms) but the normal compensatory angiogenic response that should raise VEGF has been disrupted.
In normal physiology, tissue hypoxia activates HIF-1 (hypoxia-inducible factor 1), which enters the nucleus and transcriptionally upregulates VEGF, driving angiogenesis and vascular expansion to restore oxygen delivery. In CIRS patients, the biotoxin inflammatory cascade appears to impair this HIF-1 to VEGF compensatory signaling through mechanisms that include: cytokine-mediated HIF-1 degradation, complement-driven endothelial dysfunction that prevents effective VEGFR-2 signaling, and VIP depletion (VIP normally supports pulmonary vascular regulation and endothelial VEGF production through VPAC receptor signaling).
The clinical result is a patient whose capillary bed cannot expand to compensate for inadequate oxygen delivery. Exercise that would normally trigger adaptive capillary recruitment instead produces disproportionate symptoms because the capillary density required to meet the increased oxygen demand during exertion is insufficient. This explains the characteristic CIRS post-exertional malaise where even moderate physical activity produces symptom flares lasting hours to days: it is not deconditioning but genuine capillary-level oxygen delivery failure from inadequate VEGF-driven vascular maintenance. VIP nasal spray, used in the final stages of the Shoemaker protocol, has documented VEGF-raising activity, providing the vascular regulatory support that restores capillary function and resolves the exercise intolerance and air hunger of CIRS.
4. VEGF in Non-CIRS Contexts: When Elevated VEGF Is the Concern
Malignancy and Angiogenesis
- Solid tumor angiogenesis: rapidly growing tumors outstrip their oxygen supply and produce VEGF to stimulate the new blood vessel formation required for continued tumor growth; serum VEGF is elevated in many solid tumor types including colorectal, breast, lung, ovarian, and renal cell carcinoma; VEGF is not sufficiently specific for cancer screening but elevated levels without another explanation warrant oncology evaluation
- Bevacizumab and anti-VEGF therapy: anti-VEGF antibodies (bevacizumab, ramucirumab) and VEGFR tyrosine kinase inhibitors (sunitinib, sorafenib, axitinib) are standard treatments for many solid cancers; they deprive tumors of their angiogenic support; VEGF monitoring during anti-VEGF therapy can indicate therapeutic response or resistance emergence
- Myeloproliferative disorders: polycythemia vera, essential thrombocythemia, and chronic myeloid leukemia produce elevated VEGF from neoplastic myeloid cells and elevated platelet VEGF stores; serum VEGF interpretation requires platelet count context in these conditions
Metabolic and Inflammatory Conditions
- Diabetic retinopathy: retinal ischemia from diabetic microangiopathy drives compensatory VEGF overproduction in the retina, producing the pathological retinal neovascularization (proliferative diabetic retinopathy) that threatens vision; intravitreal anti-VEGF injections (ranibizumab, aflibercept, bevacizumab) are the primary treatment for proliferative diabetic retinopathy and diabetic macular edema
- Wound healing and tissue repair: VEGF rises transiently during wound healing as part of the normal angiogenic response to tissue injury; elevated VEGF from a known wound, surgical procedure, or recent injury is physiological and self-resolving
- Chronic inflammatory conditions: rheumatoid arthritis, inflammatory bowel disease, and psoriasis all produce elevated VEGF from activated macrophages and synoviocytes; VEGF-driven synovial pannus angiogenesis contributes to joint destruction in RA
- Obesity: adipose tissue, particularly visceral fat, produces significant VEGF; obesity-associated VEGF elevation reflects adipose expansion angiogenesis and correlates with metabolic syndrome severity
5. VIP and VEGF: The Recovery Connection
- VIP directly raises VEGF: vasoactive intestinal polypeptide nasal spray, used in steps 10 and 11 of the Shoemaker CIRS protocol, has documented VEGF-elevating activity through VPAC1 and VPAC2 receptor signaling on pulmonary endothelial cells and macrophages; VIP promotes endothelial VEGF production and reduces the complement-driven endothelial dysfunction that impairs VEGFR-2 signaling; as VIP is restored, VEGF rises toward normal and capillary density and function begin to recover
- The clinical recovery sequence: patients beginning VIP therapy after completing earlier CIRS protocol steps typically report progressive improvement in exercise tolerance, air hunger, and post-exertional malaise over 4 to 8 weeks, tracking the rising VEGF toward the 31 to 86 pg/mL reference range; complete resolution of pulmonary vascular symptoms may require 3 to 6 months of VIP therapy with continued protocol adherence
- Why VIP must come last: VIP has an extremely short half-life of approximately 2 minutes that is further shortened in the high-complement, high-cytokine environment of active CIRS; administering VIP before C4a is normalized and TGF-beta1 is reduced results in rapid VIP degradation before it can act on VEGF production; completing upstream steps creates the biochemical environment in which VIP can exert its VEGF-elevating and pulmonary regulatory effects
6. Supporting VEGF Recovery in CIRS
Primary Protocol Steps
- Complete upstream CIRS protocol steps: VEGF cannot rise in the environment of active C4a-driven complement activation, elevated TGF-beta1, and VIP depletion; exposure elimination, binder therapy, MARCoNS eradication, and sequential upstream normalization of other CIRS markers create the conditions for VEGF recovery
- VIP nasal spray at appropriate protocol stage: the most direct VEGF-elevating intervention in CIRS; compounded VIP (50mcg per puff, 4 puffs four times daily) administered after upstream steps are completed; monitor VEGF, MMP-9, and pulmonary symptom response at 30-day intervals
- Avoid VIP-depleting factors: ongoing biotoxin exposure, unresolved MARCoNS, persistent high C4a, and continued TGF-beta1 elevation all prevent VIP from acting effectively and therefore prevent VEGF recovery
Angiogenic Support
- Moderate exercise (within tolerance): gentle aerobic exercise produces physiological HIF-1 activation and transient VEGF elevation that supports angiogenic adaptation; must be kept well below post-exertional malaise threshold in CIRS; short walks, gentle cycling, or pool walking before progressing intensity as VEGF recovers
- Intermittent hypoxic training (advanced): deliberate brief hypoxic exposure (altitude training, hypoxic tents) activates HIF-1 and VEGF more potently than normoxic exercise; used in performance sports; theoretical benefit for VEGF recovery in CIRS but requires specialist supervision and is not appropriate for patients with significant cardiac or pulmonary disease
- Omega-3 fatty acids (3 to 4g EPA and DHA daily): support endothelial function and reduce the inflammatory endothelial dysfunction that impairs VEGFR-2 signaling; indirect support for VEGF pathway restoration
- Vitamin D optimization (60 to 80 ng/mL): VDR signaling on endothelial cells supports VEGF receptor expression and endothelial responsiveness to VEGF; deficiency impairs the vascular response to VEGF even when VEGF levels are adequate
Pulmonary and Vascular Support
- Breathing exercises and respiratory physiotherapy: diaphragmatic breathing, pursed-lip breathing, and inspiratory muscle training support pulmonary function during the period of VEGF-driven capillary hypoperfusion; cannot substitute for VEGF normalization but reduce the functional impact of reduced pulmonary vascular capacity
- Magnesium (400 to 600mg daily as glycinate or malate): pulmonary vascular smooth muscle relaxation is magnesium-dependent; magnesium deficiency worsens pulmonary vascular tone; optimization supports pulmonary circulation during CIRS recovery
- CoQ10 (200 to 400mg as ubiquinol daily): supports mitochondrial energy production in cells working under the oxygen delivery constraints of low VEGF; reduces the cellular energy deficit that contributes to post-exertional malaise
- Pacing and activity management: during the period of low VEGF and impaired exercise tolerance, structured pacing prevents the post-exertional crashes that set back recovery; heart rate monitoring (keeping below anaerobic threshold) guides safe exercise intensity until VEGF recovers
7. Related Lab Tests
VIPVIP Directly Raises VEGF; the Primary Intervention for Low VEGF in CIRS
→
C4aPrimary CIRS Complement Marker; Its Normalization Allows VEGF to Recover
→
MSHMaster CIRS Regulatory Marker; MSH Depletion Correlates with Low VEGF
→
MMP-9Neuroinflammation Companion; Both MMP-9 and VEGF Track Treatment Progress
→
GDF-15Mitochondrial Stress and Vascular Health Longevity Companion
→
TGF-beta1Pro-Fibrotic CIRS Driver; Its Reduction Precedes VEGF Recovery
→
8. Clinical Perspective
Clinical Perspective
VEGF is the marker that explains the air hunger and exercise intolerance in CIRS patients who are being told they are simply deconditioned or anxious. When VEGF is 18 pg/mL, which is well below the lower reference limit of 31 pg/mL, the angiogenic signal maintaining capillary density in muscles and lung tissue is insufficient for the oxygen delivery demands of any meaningful physical activity. These patients are not deconditioned: they have a measurable deficiency in the growth factor required to maintain the capillary beds that deliver oxygen to their tissues. A 42-year-old who could run a half-marathon three years ago and now becomes breathless walking up stairs does not have anxiety; her VEGF is 18 pg/mL and her VIP is 14 pg/mL, and together those two numbers explain exactly what is happening in her vascular system. The conversation with patients changes completely when you can show them the mechanism. And when VIP therapy at the appropriate protocol stage raises her VEGF from 18 to 54 pg/mL over 8 weeks, and she reports being able to walk a mile without symptomatic crash for the first time in years, the connection between the number and the clinical response is exactly the kind of measurable, mechanistic improvement that defines evidence-forward medicine.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
9. Frequently Asked Questions
Why is VEGF low in CIRS when patients have tissue hypoxia?
In normal physiology, tissue hypoxia activates HIF-1 which upregulates VEGF to drive angiogenesis and restore oxygen delivery. In CIRS, the biotoxin inflammatory cascade disrupts this HIF-1 to VEGF compensatory pathway through cytokine-mediated HIF-1 degradation, complement-driven endothelial dysfunction, and VIP depletion. The result is tissue hypoxia without the normal angiogenic correction: inadequate VEGF means the capillary bed cannot expand to meet oxygen demand, producing air hunger, exercise intolerance, and post-exertional malaise.
How does VIP raise VEGF in CIRS treatment?
VIP nasal spray signals through VPAC1 and VPAC2 receptors on pulmonary endothelial cells and macrophages, directly stimulating endothelial VEGF production and reducing the complement-driven endothelial dysfunction that impairs VEGFR-2 signaling. As VIP is restored through nasal spray at the appropriate protocol stage, VEGF rises toward the reference range, capillary density and function begin to recover, and the exercise intolerance and air hunger of CIRS progressively resolve over 4 to 8 weeks of therapy.
When should elevated VEGF raise cancer concern?
Unexplained VEGF above 200 pg/mL without a known physiological cause (recent surgery, active wound healing, intense exercise training program, known inflammatory condition) warrants evaluation for malignancy. Many solid tumors produce VEGF to support their angiogenic growth requirements. In a CIRS evaluation context, VEGF is expected to be low to normal; markedly elevated VEGF in a patient being evaluated for CIRS should prompt oncology evaluation rather than attribution to biotoxin illness, as cancer and CIRS can coexist and cancer-driven VEGF elevation would not be captured in the CIRS treatment framework.
Can VEGF be raised through lifestyle interventions in CIRS?
Moderate aerobic exercise produces physiological HIF-1 activation and transient VEGF elevation; however, CIRS patients with low VEGF and exercise intolerance must keep activity within the post-exertional malaise threshold, making aggressive exercise impossible before VEGF recovers. The most effective VEGF-raising interventions in CIRS are the protocol steps that remove the upstream suppression: confirmed biotoxin exposure elimination, binder therapy reducing C4a, sequential upstream normalization, and ultimately VIP nasal spray. Adjunctive omega-3 fatty acids and vitamin D optimization support endothelial health and VEGFR-2 responsiveness but cannot compensate for the VIP-VEGF pathway disruption of active CIRS.
How does low VEGF produce post-exertional malaise in CIRS?
Post-exertional malaise (PEM) in CIRS reflects the mismatch between oxygen demand during exertion and the capillary oxygen delivery capacity limited by low VEGF. With insufficient capillary density and vascular maintenance signaling, even moderate exertion produces relative tissue hypoxia in muscle beds. This triggers compensatory metabolic shifts including lactate accumulation at lower workloads than normal, increased oxidative stress from mitochondrial oxygen deficit, and immune activation from exercise-triggered damage-associated molecular patterns (DAMPs) in a setting where MMP-9 and complement are already elevated. The result is a symptom flare that can persist for 12 to 48 hours or longer after physical activity that would be trivially tolerated in a healthy individual with normal VEGF and capillary function.
Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Low VEGF in CIRS explains why patients experience air hunger and post-exertional malaise: the growth factor maintaining their capillary bed is insufficient for oxygen delivery demands. VIP therapy restores it.
VEGF is the vascular marker of CIRS severity. Schedule a consultation for a comprehensive CIRS evaluation including VEGF, VIP, and a complete Shoemaker panel with structured treatment planning.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.